Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H3D4

UPID:
P63_HUMAN

ALTERNATIVE NAMES:
Chronic ulcerative stomatitis protein; Keratinocyte transcription factor KET; Transformation-related protein 63; Tumor protein p73-like; p40; p51

ALTERNATIVE UPACC:
Q9H3D4; O75080; O75195; O75922; O76078; Q6VEG2; Q6VEG3; Q6VEG4; Q6VFJ1; Q6VFJ2; Q6VFJ3; Q6VH20; Q7LDI3; Q7LDI4; Q7LDI5; Q96KR0; Q9H3D2; Q9H3D3; Q9H3P8; Q9NPH7; Q9P1B4; Q9P1B5; Q9P1B6; Q9P1B7; Q9UBV9; Q9UE10; Q9UP26; Q9UP27; Q9UP28; Q9UP74

BACKGROUND:
The tumor protein 63, or p63, is a key transcription factor involved in the regulation of developmental processes, including epithelial stratification and limb formation. It acts by modulating the expression of genes critical for cell cycle control and apoptosis, particularly in response to genotoxic stress. The protein's ability to activate or repress transcription is isoform-specific, highlighting its versatile role in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of p63 could open doors to potential therapeutic strategies. Its involvement in a spectrum of ectodermal dysplasia syndromes and limb malformations suggests that modulating p63 activity could have therapeutic benefits. Research into p63's regulatory mechanisms may lead to breakthroughs in treating conditions like Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.